Related Experiment Video

Updated: May 9, 2026

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2

Koga Komatsu1, F Gregory Buchanan, Sharada Katkuri

  • 1Department of Cell/Developmental Biology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, USA.

Gastroenterology
|August 9, 2005
PubMed
Abstract

Insights

The study shows that cyclooxygenase-2 (COX-2) is crucial for MEK1-induced oncogenic transformation in rat intestinal cells. Inhibiting COX-2 reduces MEK-driven tumor growth by increasing apoptosis, highlighting COX-2 as a therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Biology

Background:

  • The mitogen-activated protein kinase (MEK) pathway regulates cell growth and differentiation.
  • Aberrant MEK signaling can cause oncogenic transformation.
  • MEK signaling influences cyclooxygenase-2 (COX-2) expression, a factor in colorectal cancer.

Purpose of the Study:

  • To investigate the role of COX-2 in MEK1-induced oncogenic transformation.
  • To determine if COX-2 mediates MEK1's effects in non-transformed rat intestinal epithelial cells.

Main Methods:

  • Established constitutively active MEK1 (CA-MEK) transfected rat intestinal cells.
  • Assessed soft agar colony formation and in vivo tumorigenicity.
  • Evaluated apoptosis using Annexin V assay and analyzed COX-2 gene expression.
  • Administered celecoxib to xenografted mice to inhibit COX-2.

Main Results:

  • CA-MEK cells formed colonies and tumors, resisting apoptosis.
  • MEK activation increased COX-2, Bcl-X(L), Mcl-1, and PGI(2)/PGE(2) levels.
  • COX-2 inhibition significantly reduced MEK-induced tumor growth via enhanced apoptosis.

Conclusions:

  • COX-2 and its lipid products are key players in MEK-induced cellular transformation.
  • Targeting COX-2 may be a viable strategy for treating MEK-driven cancers.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...